We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The addition of pharmacomechanical ...

Please provide your email address to receive an email when new articles are posted on . The time has probably come for hematologist/oncologists to think more about ...

(HealthDay News) — The addition of pharmacomechanical thrombolysis does not reduce the risk of post-thrombotic syndrome among patients with acute proximal deep vein thrombosis, according to a study ...

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine through education and research, today announced results from the Late-Breaking Clinical Trials ...

Landmark study shows clot-busting drugs not recommended for most patients with secondary blood clots in the legs. A landmark study to examine the ability of imaging-guided treatment to address ...

Am J Health Syst Pharm. 2006;63(20):S5-S15. Patient demographics and pre-index clinical characteristics were similar between the subgroups of patients who developed DVT/PE ( Table 1). The average age ...

Medically reviewed by Amelia MacIntyre, DO Key Takeaways Recovery from a pulmonary embolism can take weeks to months. Keeping ...

In a recent study published on the preprint server medRxiv*, researchers aimed to better understand the population-level thrombotic risks post COVID-19 vaccination with both the ChAdOx1-S and BNT162b2 ...

In estimating the burden of disease that is associated with patients at high risk of DVT or PE, health care providers and managed-care organizations should consider the entire continuum of care for ...